NEW YORK (GenomeWeb News) – Quest Diagnostics has entered into an accelerated share repurchase deal with Morgan Stanley to buyback about $350 million of Quest's common stock as part of its share repurchase program. The deal is expected to complete in the fourth quarter. The company last month announced the board approved an increase to its share repurchase authorization of $1.0 billion.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.